Menopause and bone health: what changes and what to discuss

Many women hear that menopause is hard on the bones and are left wondering how much, for how long, and what can be done. The short answer is that the fall in estrogen does speed up bone loss for a period, but the effect varies and several other factors matter too. This page explains the link, the risk factors that tend to add to it, what public guidance says about screening, and how hormone therapy is discussed by authoritative sources. It does not recommend for or against any treatment.

How estrogen is linked to bone

Bone is living tissue that is constantly broken down and rebuilt. Estrogen helps keep that balance in favor of keeping bone. The Bone Health and Osteoporosis Foundation (BHOF) says that when estrogen levels drop, many women lose bone density, and that for midlife women the drop that comes with menopause can lead to rapid bone loss (BHOF: Hormones and Healthy Bones). It adds that bone loss can start speeding up when estrogen begins to decline during perimenopause, the transition before periods stop.

The US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) makes a similar point, saying that for many women osteoporosis begins to develop a year or two before menopause, and that low estrogen after menopause is one of the hormone changes that raise risk (NIAMS: Osteoporosis). The condition itself is covered in osteoporosis and bone health.

How much bone loss, and for how long

The BHOF booklet states that for many women, rapid bone loss takes place during the five to seven years after menopause, and that women can lose up to 20 percent of their bone density in that time. It also notes that in the early years after menopause the risk of spine fractures increases. After the rapid phase, loss tends to be slower.

Two cautions apply. First, these are figures for many women, not a prediction for one person. Second, bone density is only one part of fracture risk, which also depends on age, fall risk and other health factors.

Other risk factors that add up

NIAMS lists several factors that raise osteoporosis risk, and many women have more than one. They include female sex, increasing age, a small or slender frame, family history (a parent with osteoporosis or a hip fracture), a diet low in calcium and vitamin D, and low physical activity. Long-term use of some medicines can matter too, among them glucocorticoid steroids, certain anti-seizure and cancer medicines, and some others on its list. Smoking and heavy alcohol use are also named.

NIAMS also notes that low estrogen from the abnormal absence of periods before menopause, for example in hormone disorders or with extreme exercise, can raise risk. If you take any long-term medicine and are worried, ask your prescriber rather than stopping it.

Screening: what guidance says

Bone density testing, usually a DXA scan, is the main screening tool, and you can read how it works in bone density test (DXA) explained. NIAMS reports that the US Preventive Services Task Force recommends screening women over age 65, and women of any age who have factors that increase their chance of osteoporosis (NIAMS: Osteoporosis diagnosis, treatment and steps to take).

That is one country's guidance. Other countries and professional societies set different ages and thresholds. If you are approaching or past menopause, a useful step is asking your own doctor which approach applies where you live and whether your risk factors call for earlier testing.

Lifestyle measures, at a general level

NIAMS lists staying physically active with weight-bearing exercise such as walking, drinking alcohol in moderation, quitting smoking, and eating a diet rich in calcium and vitamin D. These measures support bone health at any stage, and they do not replace medical care if osteoporosis is found. More detail is in calcium and vitamin D basics and exercise and bone loading.

Hormone therapy and bone: what sources say

Hormone therapy (HT, also called HRT) replaces some of the estrogen the body stops making. Whether to use it is a decision for the individual woman and her clinician, and this page takes no side. What follows is what authoritative sources state.

On the bone side, the NHS says HRT helps prevent osteoporosis by raising estrogen, and that this is especially relevant if periods stop before age 45 (NHS: Benefits and risks of HRT). The BHOF booklet says estrogen can increase bone density and lower fracture risk, and that the US Food and Drug Administration has approved estrogen and hormone therapy to prevent osteoporosis in postmenopausal women.

On the risk side, the same sources add caveats. The NHS says serious side effects are usually very low, but combined HRT slightly raises breast cancer risk (roughly 5 extra cases per 1,000 women after 5 years) and tablets slightly raise the risk of blood clots and stroke. The BHOF booklet reports that large studies found HT slightly increases the risk of heart attack, stroke, venous clots and breast cancer, and that the FDA recommends looking at other osteoporosis medicines first. The UK medicines regulator says the bone benefit of HRT diminishes soon after stopping, and that for prevention of osteoporosis it should be used only in women who cannot use other medicines (MHRA Drug Safety Update: HRT updated advice).

In short, bone benefit is recognised, and so are risks that depend on the type of therapy, dose, duration and personal history. The NHS describes benefits as likely to outweigh risks for women under 60 with menopause symptoms who are not at high risk of breast cancer or clots, and says a GP can help decide. Other medicines for bone are outlined in how osteoporosis medicines work.

Honest limits

Guidance is shifting, and advice differs between countries and between individuals. This page is educational and does not interpret anyone's results. Individual care varies, and your own doctor or specialist has the final word.

The short version

Estrogen decline around menopause speeds bone loss for several years, though how much differs widely between women. Risk factors add up, screening guidance varies by country, and hormone therapy has recognised bone benefits alongside recognised risks. It is a conversation to have with a clinician who knows your history.